Related Experiment Videos
Pravastatin experience in elderly and non-elderly patients
M J Mellies1, A R DeVault, K Kassler-Taub
1Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543-4000.
Insights
Pravastatin effectively lowers cholesterol in elderly and non-elderly patients, demonstrating similar safety and efficacy profiles for both groups. This HMG CoA reductase inhibitor is a well-tolerated option for managing hypercholesterolemia in older adults.
Area of Science:
- Cardiology
- Pharmacology
- Geriatrics
Background:
- Elevated cholesterol is linked to coronary heart disease (CHD) morbidity and mortality.
- Lowering cholesterol is a key strategy for CHD prevention.
- Elderly individuals represent a significant population at risk for hypercholesterolemia and CHD.
Purpose of the Study:
- To evaluate the safety and efficacy of pravastatin in elderly (≥65 years) versus non-elderly hypercholesterolemic patients.
- To assess the long-term effectiveness and tolerability of pravastatin in different age groups.
- To compare pravastatin's lipid-lowering effects and adverse event profiles across age demographics.
Main Methods:
- Pooled analysis of individual patient data from six double-blind, randomized, multicenter studies.
- Comparison of pravastatin's effects in elderly (≥65 years) and non-elderly patient cohorts.
- Assessment of lipid profiles (total cholesterol, LDL, HDL, triglycerides) and adverse events over short-term (8-16 weeks) and long-term (≥24 months) study periods.
Main Results:
- Pravastatin (20 or 40 mg daily) significantly reduced total cholesterol (19-25%) and LDL cholesterol (25-33%), with a modest increase in HDL cholesterol (5-10%).
- Lipid-lowering effects and improvements were sustained long-term (over 24 months) in both elderly and non-elderly patients.
- Incidences of adverse drug events and laboratory abnormalities were similar between elderly and non-elderly groups, with very low discontinuation rates (<1% short-term, 0.4% long-term pravastatin group).
Conclusions:
- Pravastatin is a safe and effective HMG CoA reductase inhibitor for long-term management of hypercholesterolemia in elderly patients.
- The drug demonstrates comparable efficacy and tolerability in elderly and non-elderly populations.
- Pravastatin offers a convenient once-daily dosing regimen for cholesterol management in older adults.
Abstract:
Epidemiologic evidence linking elevated cholesterol concentrations and coronary heart disease (CHD) through the eighth decade of life provides a rationale for lowering cholesterol concentrations to reduce morbidity and mortality from CHD. Pravastatin, a well tolerated HMG CoA reductase inhibitor with a convenient once-daily dosing regimen, has been shown to effectively lower total and low density lipoprotein (LDL) cholesterol. Individual data from more than 1800 hypercholesterolemic patients enrolled in six double-blind, randomized, multicenter studies were pooled and then analyzed to compare the safety and efficacy of pravastatin in the elderly (i.e., patients at least 65 years old) and the non-elderly. In short-term studies (8-16 weeks), response was dose-related and similar in elderly and non-elderly subjects. Pravastatin 20 or 40 mg daily lowered total cholesterol 19-25%, LDL-cholesterol 25-33%, and triglycerides 14-23%; high density lipoprotein (HDL) cholesterol increased 5-10%. During long-term studies, improvements were sustained for more than 24 months in both the non-elderly and elderly. The incidences of adverse drug events and laboratory abnormalities were similar in the elderly and non-elderly patients in all groups (active treatment control with resin, pravastatin alone, or combination therapy). In short-term studies, treatment was discontinued because of adverse events in < 1% of all patients treated with pravastatin (all doses) or placebo. The frequency and profile of adverse events were similar among patients treated with pravastatin or placebo. In long-term studies, treatment was discontinued in 0.4% of patients in the pravastatin group and in 0.3% of the patients in the bile-acid-binding resin group. If drug therapy is warranted, pravastatin appears to be safe and effective for long-term use in elderly patients with hypercholesterolemia.